Physician profile
Michael Ingram
NPI 1295767283
$255,284.51
in general payments reported to CMS, 2019-2025
24 companies · $36K in 2025
The $36K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $27K · 2021: $29K · 2022: $44K · 2023: $18K · 2024: $45K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $13K · Travel and Lodging: $11K · Food and Beverage: $5,137 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,100.00 |
| Consulting Fee | $12,680.25 |
| Travel and Lodging | $10,812.79 |
| Food and Beverage | $5,136.83 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $91,892.73 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $73,024.00 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $33,941.19 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25,641.91 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $21,331.75 | 2019-2023 | Austedo Xr, Uzedy, Austedo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,538.66 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rejoyn |
| Neurocrine Biosciences, INC. | $359.29 | 2019-2025 | Ingrezza |
| Validus Pharmaceuticals LLC | $346.16 | 2019-2021 | |
| Lundbeck LLC | $255.29 | 2019-2025 | Rexulti |
| Abbvie INC. | $206.10 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $150.94 | 2019-2021 | |
| Axsome Therapeutics, INC. | $130.94 | 2023-2025 | Auvelity |
| Indivior INC. | $96.59 | 2019-2025 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $91.06 | 2019-2025 | Trintellix |
| Sage Therapeutics, LLC | $88.30 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $53.25 | 2022 | |
| Uswm, LLC | $27.84 | 2023 | Zimhi, Lucemyra |
| Antares Pharma, INC. | $17.85 | 2024 | Xyosted |
| Corium, LLC | $17.78 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $17.65 | 2019 | |
| Tris Pharma INC | $15.79 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $12.71 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.